5 Best Regional Bank Stocks To Buy For 2015

5 Best Regional Bank Stocks To Buy For 2015: Athersys Inc.(ATHX)

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating cardiovascular disease, neurological conditions, inflammatory and immune disorders, and other conditions. Its product pipeline includes MultiStem, a novel allogeneic approach to stem cell therapy and regenerative medicine for treating a range of diseases. The company is also involved in the development of novel small molecule compounds for applications in indications, such as obesity and other areas, including the treatment of neurological conditions, and for the modulation of stem cells or related applications in the regenerative medicine area. It has product co-development collaboration with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease for the worldwide market; Angiotech Pharmaceuticals, Inc. to develop and commerciali ze MultiStem to treat certain cardiovascular diseases, such as acute myocardial infarction; and RTI Biologics, Inc. to develop and commercialize biologic implants for certain orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.

Advisors' Opinion:

• [By Lauren Pollock var popups = dojo.query(".socialByline .popC"); popups.forEach]

  Biotechnology company Athersys Inc.(ATHX) said interim results of a mid-stage study of its MultiStem cell therapy for ulcerative colitis failed to show meaningful benefit in certain cases, though the treatment had favorable safety and tolerability. Shares plunged 52% to $1.30 premarket.

• [By Roberto Pedone]

  Athersys (ATHX) is a biopharmaceutical company focused in the field of regenerative medicine. This stock closed up 4% to $1.79 in Thursday's trading session.

  Thursday's! Range: $1.68-$1.80
  
  52-Week Range: $0.95-$2.42
  
  Thursday's Volume: 270,000
  
  Three-Month Average Volume: 323,188

  From a technical perspective, ATHX bounced notably higher here right off its 50-day moving average of $1.67 with decent upside volume. This stock recently pulled back from $1.99 to its 50-day at $1.67. Shares of ATHX may now be down with that pullback, since the stock is starting to trend higher and move within range of triggering a near-term breakout trade. That trade will hit if ATHX manages to take out some near-term overhead resistance levels at $1.90 to $1.99 with high volume.

  Traders should now look for long-biased trades in ATHX as long as it's trending above its 50-day at $1.67 and then once it sustains a move or close above those breakout levels with volume that hits near or above 323,188 shares. If that breakout triggers soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $2.16 to $2.25. Any high-volume move above those levels will put its 52-week high at $2.42 into range for shares of ATHX.

• [By Roberto Pedone]

   

  Another under-$10 biotechnology player that's starting to trend within range of triggering a big breakout trade is Athersys (ATHX), which focuses on the research and development activities in the field of regenerative medicine. This stock has been destroyed by the bears over the last six months, with shares off sharply by 62%.

  If you look at the chart for Athersys, you'll see that this stock has been downtrending badly for the last two months and change, with shares moving lower from its high of $1.99 to its recent low of $1.31 a share. During that downtrend, shares of ATHX have been making mostly lower highs and lower lows, which is bearish technical price action. That said, shares of ATHX are now starting to bounce off some near-term support at $1.31 and it's now starting to trend within range of triggering a big breakout trade above some! near-ter! m overhead resistance levels.

  Market players should now look for long-biased trades in ATHX if it manages to break out above some near-term overhead resistance levels at $1.40 to $1.49 a share and then back above its 50-day moving average of $1.52 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 384,325 shares. If that breakout hits soon, then ATHX will set up to re-test or possibly take out its next major overhead resistance levels at $1.70 to $1.78 a share, or even $1.99 a share.

  Traders can look to buy ATHX off weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support at $1.31 a share. One can also buy ATHX off strength once it starts to bust above those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  Read More: Warren Buffett's Top 10 Dividend Stocks

• [By Lisa Levin]

  Athersys (NASDAQ: ATHX) shares fell 56.04% to reach a new 52-week low of $1.20 on failed trial results for ulcerative colitis.

  Posted-In: 52-Week LowsNews Movers & Shakers Intraday Update Markets

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/5-best-regional-bank-stocks-to-buy-for-2015-2.html